| Under the chemotherapy,radiotherapy,biotherapy or targeted therapy, those patients with hormone receptors negative (HR-) breast cancer after surgical services, could gain a suvival time; while numbers of clincal study demonstrated that the patients with HR- breast cancer has shorter Disease-free Survival (DFS) and Overall Survival(OS) than hormone receptors positive patients. It is a plum in clincal study, that searching for the new method to prolong HR- patients'DFS and OS, and reduce the rate of recurrence and metastasis.Traditional Chinese Medicine treatment based on the concept of wholism and categorical identification, could relieve the local symptom after surgry,the side-effect of chemotherapy and radiotherapy, regulate the internal environment of the body, in order to improve patients'quality of life, and prolong the median disease free survival.The Ru Ji Fang prepared by our hospital,and in many years'clinical practice,we find that RujiFang could relieve clinical symptom,improve quality of life and survival time. There are not enough objective data to prove RujiFang's fanction, and our study will research RujiFang's prevention effection from the recurrence and metastasis for breast cancer patients with hormone receptors negative.ObjectiveThe study is to reveal RujiFang's therapy effection on clincal symptom,the quality of life,survival time and the time of tumors'recurrence and metastasis in hormone receptors negative breast cancer.MethodsA retrospective analysis for a group of breast cancer patients. All patients accept a long-term of follow-up,and select about 42 qualified female cases with hormone receptors negative breast cancer and finished surgical thrapy. According to the treatment and medcine records in follow-up period,all patients divided into treated group and controled group.In treated group, patients after a combined treatment, need a RujiFang therapy more than 3 months; patients in controled group followed regularlly, but cannot accept any kinds of antieoplaston, include Chinese Anti-cancer Medicine. Before the study and after the final follow up, record the score of clinical symptom,laboratory,the scores of ECOG and quality of life (Functional Assessment of Cancer Therapy-Breast Cancer FACT-B),and the Overall Survival (OS),the time of recurrence or metastasis, compared the difference in the interior-group and inter-group, to obtain the statically difference.ResultsPartâ… 1,RujiFang is helpful to relieve the clinical sympotm for the patients with hormone receptors negative breast cancer:the total marked effective rate of treated group is 48%, effective rate is 52%, and a 100% total remission rate, compared with the controled group, could have statistical singnificance (P<0.05)2,RujiFang has the funcation of improve abnormal liver function after chemotherapy, and compered with the controled group,could have statistical singnificance (P<0.05)3,RujiFang can improve the patients' quality of life:(1) PS(ECOG) score:compare the score before treatment, there was no significent difference between the two groups (P>0.05); after the study,the score of the treated group is lower than the controled group's, the difference have statistical sense (P<0.05); there is not significent change in the PS score before and after treatment (P>0.05), while in the controled group, after the treatment, the score was significantly higher than before (P<0.05)(2) The results of FACT-B determination:there were no signifcant difference between two groups' scores before the study (P>0.05); in post-treatment, the scors of Physical Well-Being,Emotional Well-Being in the treated group are less than the control group's (P<0.05).Before and after the treatments, in the treated group, patients' Physical Well-Being and Emotional Well-Being have significantly improved (P<0.01); Social-Family Well-Being and Functional Well-Being are improved significantly (P<0.05); In control grou, the score of Functional Well-Being,Affixation Attention after treatment were markedly lower (P<0.05); Physical Well-Being,Emotional Well-Being,Social-Family Well-Being have no significantly change, before and after the treatment (P>0.05)Partâ…¡1,FLF,FDM and OS:in the treated group, the median OS is 30 months, mean OS is 37.38 months, median DFS is 30 months, mean DFS is 37.19 months; in the controled group, the median OS is 17months, mean OS is 20.93 months, median DFS is 13 months, mean DFS is 16.26 months. During follow-up period, there are 12 cases'recurrence or metastases, incidence rate is 28.57%(12/42):2 casess'recurrence (2/21,28.57%) and 4 cases' metastases(4/21,19.05%), in the treated group; 6 cases' metastases(6/21,28.57%) and all happens in 16 months, in the control group. Comparison among groups there are significatly difference on the OS and DFS(Log rank test P=0.000).2,The 1.5-year OS,1.5-year recurrence and metastsis rates:1.5- year OS:71.43% (the treated group 15/21) VS.47.62% (the controled group 10/21); the 1.5-year FLF and/or FDM:61.90%(the treated group 13/21) VS.19.05% (the controled group 4/21); the recurrence and metastasis rates for 1.5 years:9.52% (the treated group 2/21) VS.28.57% (the controled group 6/21).3,The 3-year OS,FLF and FDM:the 3-year OS:42.86%(the treated group 9/21) VS.19.05% (the controled group 4/21); 3-year FLF and/or FDM:38.10% (the treated group 8/21) VS.14.29% (the control group 3/21); 3-year recurrence and metastasis rates:4.76% (the treated group 1/21),0 cases in the control group.4,5-year OS,1.5-year recurrence and metastsis rates:in the treated group,5-year OS is 28.57% (6/21),5-year local recurrence rates is 9.68%; there were no case followed or beyond 5 years in the controled group. 5,The univariate analyses for the risk factors of recurrence and/or metastasis:age and the number of lymph nodes have positive correlation with the risk of recurrence and/or metastasis (P<0.05); and this kind of risk cuold be reduced by the therapy of RujiFang significantly (P<0.05). 6,The univariate analyses for the risk factors of death:The factors such as young,premenopausal,positive C-erbB-2 expression could increase the risk of Breast Cancer related death (P<0.05); and the therapy of RujiFang could reduce the risk of Breast Cancer related death (P<0.05).The Kaplan-Meier test show:those factors, such as age,menstrual state,immunohistochemical type,clinical TNM stage,the number of lymph nodes,rediotherapy,neoadjuvant chemotherapy,have no significantly influence to OS or DFS (P>0.05)ConclusionPartâ… 1,RujiFang could relieve the clinical sympotm for the patients with hormone receptors negative breast cancer.2,RujiFang could improve the chemotherapy and/or radiotherapy related abnormal liver function3,RujiFang could improve the quality of life for the patients with hormone receptors negative breast cancer after complex treatment.Partâ…¡1,RujiFang could prolong the OS and DFS of patients with hormone receptors negative breast cancer.2,RujiFang for hormone receptors negative breast cancer patients, could delay the recurrence and/or metastasis time.3,The univariate analyses show:age,the number of lymph nodes could increase the risk of recurrence and/or metastasis; age,premenopausal could increase the risk of hormone receptors negative Breast Cancer related death.4,The univariate analyses show:RujiFang could significently reduce the recurrence and/or metastasis risk after the complex treatment for hormone receptors negative Breast Cancer pantients. |
PDF Full Text Request